Literature DB >> 30607560

A new approach to vocal cord leukoplakia and evaluation of proton pump ınhibitor treatment.

Seda Sezen Goktas1, Remzi Dogan2, Alper Yenigun2, Omer Faruk Calim2, Orhan Ozturan2, Selahattin Tugrul2.   

Abstract

PURPOSE: Our aim is identify a new approach to vocal cord leukoplakia treatment and detect to efficiency of proton pump inhibitors. STUDY
DESIGN: Prospective, nonrandomized experimental clinical trial.
METHODS: A 'First Assessment Scale' was prepared. This scale included the lesion's and the patient's characteristics. Using this scale, 24 patients included to the study. 20 mg rabeprazole twice daily was applied to all patients. At the end of 3rd month, a 'Second Assessment Scale' was used and two groups created. In group 1, 19 patients were accepted to responsive for the therapy and received the same therapy. The group 2 was included five patients that accepted unresponsive to treatment and directed to surgery. All patients received the same treatment additionally 3 months. At the end of 6th month, the Reflux Symptom Index (RSI), the Reflux Finding Score (RFS) and the Red-Green-Blue (RGB) values evaluated and comparisons were made.
RESULTS: The RSI and RFS values were significantly decreased in all patients. The Red values were significantly decreased with treatment in group 1, but the Green and Blue values were not. In group 2, the RGB values were not showed the significant differences. In conclusion, seven patients (29,2%) showed complete lesion regression, 12 patients (50%) showed partial lesion regression and five patients (20,8%) showed no response to treatment.
CONCLUSIONS: The proton pump inhibitor treatment may be beneficial for the selected patients. The scales that we prepared were useful for lesion assesment.

Entities:  

Keywords:  Laryngopharyngeal reflux; Leukoplakia; Precancerous; Proton pump inhibitor; Rabeprazole; Vocal cord leukoplakia

Mesh:

Substances:

Year:  2019        PMID: 30607560     DOI: 10.1007/s00405-018-05273-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  26 in total

1.  CANCER OF THE LARYNX: IS IT PRECEDED BY A RECOGNIZABLE PRECANCEROUS CONDITION?

Authors:  C Jackson
Journal:  Ann Surg       Date:  1923-01       Impact factor: 12.969

2.  Use Videostrobokymography to Quantitatively Analyze the Vibratory Characteristics Before and After Conservative Medical Treatment of Vocal Fold Leukoplakia.

Authors:  Xiao-Wei Gao; Yong-Wang Huang; Li-Yan Liu; Jie Ouyang
Journal:  J Voice       Date:  2015-05-20       Impact factor: 2.009

3.  High incidence of laryngopharyngeal reflux in patients with head and neck cancer.

Authors:  M P Copper; C F Smit; L D Stanojcic; P P Devriese; P F Schouwenburg; L M Mathus-Vliegen
Journal:  Laryngoscope       Date:  2000-06       Impact factor: 3.325

4.  Positive therapy of andrographolide in vocal fold leukoplakia.

Authors:  Jue Xu; Tao Xue; Ying Bao; Dong-Hai Wang; Bing-Liang Ma; Chen-Yi Yin; Guang-Hui Yang; Gang Ren; Long-Jiang Lan; Jian-Qiu Wang; Xiao-Lan Zhang; Yu-Qin Zhao
Journal:  Am J Otolaryngol       Date:  2013-12-20       Impact factor: 1.808

5.  Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial.

Authors:  Paul K Y Lam; Manwa L Ng; Ting K Cheung; Birgitta Y H Wong; Victoria P Y Tan; Daniel Y T Fong; William I Wei; Benjamin C Y Wong
Journal:  Clin Gastroenterol Hepatol       Date:  2010-03-18       Impact factor: 11.382

6.  Is GERD a risk factor for laryngeal cancer?

Authors:  Mohammed A Qadeer; Natalie Colabianchi; Michael F Vaezi
Journal:  Laryngoscope       Date:  2005-03       Impact factor: 3.325

7.  Bile reflux as possible risk factor in laryngopharyngeal inflammatory and neoplastic lesions.

Authors:  J Galli; L Calò; S Agostino; G Cadoni; B Sergi; R Cianci; G Cammarota
Journal:  Acta Otorhinolaryngol Ital       Date:  2003-10       Impact factor: 2.124

Review 8.  Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association.

Authors:  Michael F Vaezi; Douglas M Hicks; Tom I Abelson; Joel E Richter
Journal:  Clin Gastroenterol Hepatol       Date:  2003-09       Impact factor: 11.382

Review 9.  Institutional and comprehensive review of laryngeal leukoplakia.

Authors:  Jason S Isenberg; Daniel L Crozier; Seth H Dailey
Journal:  Ann Otol Rhinol Laryngol       Date:  2008-01       Impact factor: 1.547

10.  A bama minipig model of laryngopharyngeal reflux and the change of laryngopharyngeal mucosal ultrastructure.

Authors:  Guijian Feng; Zhenyu Zhang; Chunyan Diao; Jun Jiang; Shuying Zheng; Yulan Liu
Journal:  J Neurogastroenterol Motil       Date:  2015-03-30       Impact factor: 4.924

View more
  3 in total

1.  Genetic polymorphisms and protein levels in vocal fold leukoplakia: a systematic review.

Authors:  C P Campello; M F B Lima-Silva; E L S de Lima; G R S Nunes; H A M Silva; E Dellalibera; L R P B de Britto; C A A Lemos; M T C Muniz
Journal:  Braz J Med Biol Res       Date:  2022-03-11       Impact factor: 2.590

2.  Awareness about laryngopharyngeal reflux disease among Chinese otolaryngologists: a nationwide survey.

Authors:  Shuifang Xiao; Jinrang Li; Hongliang Zheng; Xiangping Li; Hui Yang; Junbo Zhang; Xiaoxia Peng; Shuihong Zhou; Chen Zhao; Donghui Chen; Xuping Xiao; Li Shi; Hui Huangfu; Zhenfeng Tao; Xiong Chen; Yehai Liu; Shenhong Qu; Guangke Wang; Ting Chen; Xiaobo Cui; Linli Tian; Wensheng Zhou; Hongyan Fang; Yongwang Huang; Guodong Yu; Zhenqun Lin; Liang Tang; Jian He; Ruixia Ma; Zhaoyan Yu
Journal:  BMJ Open       Date:  2022-06-22       Impact factor: 3.006

3.  Videolaryngoendoscopic and Stroboscopic Evaluation in Predicting the Malignancy Risk of Vocal Fold Leukoplakia.

Authors:  Agata Leduchowska; Joanna Morawska; Wioletta Pietruszewska
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.